Total medical devices industry private equity deals in Q2 2020 worth $1.68bn were announced globally, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked an increase of 94.7% over the previous quarter and a rise of 81.6% when compared with the last four-quarter average, which stood at $922.8m.
Comparing deals value in different regions of the globe, Asia-Pacific held the top position, with total announced deals in the period worth $725.87m. At the country level, China topped the list in terms of deal value at $722.6m.
In terms of volumes, North America emerged as the top region for medical devices industry private equity deals globally, followed by Europe and then Asia-Pacific.
The top country in terms of private equity deals activity in Q2 2020 was the US with 23 deals, followed by China with eight and Belgium with two.
In 2020, as of the end of Q2 2020, medical devices private equity deals worth $2.54bn were announced globally, marking an increase of 48.3% year on year.
Medical devices industry private equity deals in Q2 2020: Top deals
The top five medical devices industry private equity deals accounted for 66.1% of the overall value during Q2 2020.
The combined value of the top five medical devices private equity deals stood at $1.11bn, against the overall value of $1.68bn recorded for the month.
The top five medical devices industry deals of Q2 2020 tracked by GlobalData were:
1) Beijing Strong Biotechnologies and Sinopharm Group’s $367.87m private equity deal with Fuzhou Maixin Biotechnology Development
2) The $337m private equity deal with Medtronic by The Blackstone Group
3) Hillhouse Capital Group and Temasek Fullerton Alpha Pte.’s $154.52m private equity deal with Shanghai Kinetic Medical
4) The $135.89m private equity deal with Abcam by Durable Capital Partners
5) Friend Capital, Guangzhou Boyi Architectural Design Institute, Meinian Onehealth Healthcare GroupLtd , New Alliance Capital, Red Horse Investment Group, Sinopec Capital and Xin Ding Capital’s private equity deal with CapitalBio for $112.98m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.